Enhancement or endangerment: a narrative review of pharmacological agents used in the fitness industry
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262886Keywords:
Performance enhancing drugs, Physical fitness, Drug misuse, Doping, Sports medicineAbstract
The global fitness industry has witnessed a significant rise in the use of pharmacological agents for enhancement of muscle mass, athletic performance, fat reduction, and physical appearance. Even though regular exercise and balanced nutrition remain the cornerstone of fitness, increasing societal pressure for rapid aesthetic transformation has contributed to the misuse of performance-enhancing drugs (PEDs). This narrative review aims to provide a comprehensive overview of the major pharmacological agents currently used in the fitness industry, including anabolic-androgenic steroids (AAS), selective androgen receptor modulators (SARMs), growth hormone and peptide analogues, stimulants, fat burners, insulin, thyroid hormones, diuretics, and post-cycle therapy drugs. A literature search was conducted using PubMed, Scopus, and Google Scholar databases using relevant keywords related to performance enhancement and fitness pharmacology. Recent evidence from clinical studies, systematic reviews, and regulatory reports were included. Advantages such as increased lean muscle mass, enhanced recovery, improved endurance, and accelerated fat loss were offered by these agents. However, their misuse is associated with serious cardiovascular, endocrine, hepatic, renal, neuropsychiatric, and metabolic complications. The emergence of social media promotion and unregulated online markets has further increased accessibility and misuse, especially among young adults. World anti-doping agency (WADA) and the United States Food and Drug Administration (FDA) continue to issue warnings regarding the safety concerns associated with these substances. This review highlights the pharmacology, benefits, adverse effects, ethical concerns, and public health implications of pharmacological agents used in the fitness industry, emphasizing the urgent need for awareness, regulation, and evidence-based education.
References
Mironica A, Popescu CA, George D, Tegzeșiu AM, Gherman CD. Social media influence on body image and cosmetic surgery considerations: a systematic review. Cureus. 2024;16(7):10.
Merino M, Tornero-Aguilera JF, Rubio-Zarapuz A, Villanueva-Tobaldo CV, Martín-Rodríguez A, Clemente-Suárez VJ. Body perceptions and psychological well-being: a review of the impact of social media and physical measurements on self-esteem and mental health with a focus on body image satisfaction and its relationship with cultural and gender factors. In Healthcare. 2024;12(14):1396.
Horn J. The dichotomy between health and drug abuse in bodybuilding. Nord Alkohol-Nark NAT. 2024;41(2):212-25.
Dandoy C, Gereige RS. Performance-enhancing drugs. Pediat Rev. 2012;33(6):265-72.
Mackey TK, Liang BA, Strathdee SA. Digital social media, youth, and nonmedical use of prescription drugs: the need for reform. J Med Internet Res. 2013;15(7):e143.
Bowers LD. Athletic drug testing. Clin Sports Med. 1998;17(2):299-318.
Walsh G. Our drug happy athletes. Sports Illustrated. 1960;13(21):26-38.
Handelsman DJ. Performance enhancing hormone doping in sport. Endotext. 2025.
Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. Jama. 1993;270(10):1217-21.
Piacentino D, Kotzalidis G, Casale A, Aromatario M, Pomara C, Girardi P, et al. Anabolic-androgenic steroid use and psychopathology in athletes. Curr Neuropharmacol. 2015;13(1):101-21.
Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Europ J Endocrinol. 2015;173(2):R47-58.
van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regulatory Toxicol Pharmacol. 2010;57(1):117-23.
Kanayama G, Hudson JI, Pope Jr HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? Drug Alcohol Dependence. 2008;98(1-2):1-2.
Pope Jr HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Rev. 2014;35(3):341-75.
Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev. 2019;7(1):84-94.
Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345-51.
Bhasin S, Krishnan V, Storer TW, Steiner M, Dobs AS. Androgens and Selective Androgen Receptor Modulators to Treat Functional Limitations Associated with Aging and Chronic Disease. J Gerontol A Biol Sci Med Sci. 2023;78(1):25-31.
Anderson LJ, Tamayose JM, Garcia JM. Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. Mol Cell Endocrinol. 2018;464:65-74.
Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD, Goldspink G. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol. 2004;555(Pt 1):231-40.
Götherström G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 2009;94(3):809-16.
Widdowson WM, Gibney J. The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin Endocrinol (Oxf). 2010;72(6):787-92.
Holt RI, Sönksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol. 2008;154(3):542-56.
Barroso O, Mazzoni I, Rabin O. Hormone abuse in sports: the antidoping perspective. Asian J Androl. 2008;10(3):391-402.
Woodgate DE, Conquer JA. Effects of a stimulant-free dietary supplement on body weight and fat loss in obese adults: a six-week exploratory study. Curr Ther Res Clin Exp. 2003;64(4):248-62.
Maughan RJ, Burke LM, Dvorak J, Larson-Meyer DE, Peeling P, Phillips SM, Rawson ES, Walsh NP, Garthe I, Geyer H, Meeusen R. IOC consensus statement: dietary supplements and the high-performance athlete. Int J Sport Nutrit Exercise Metabol. 2018;28(2):104-25.
Guest NS, VanDusseldorp TA, Nelson MT, Grgic J, Schoenfeld BJ, Jenkins ND, Arent SM, Antonio J, Stout JR, Trexler ET, Smith-Ryan AE. International society of sports nutrition position stand: caffeine and exercise performance. J Int Society Sports Nutrit. 2021;18(1):1.
Hoffman RJ, Hoffman RS, Freyberg CL, Poppenga RH, Nelson LS. Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. J Toxicol. 2001;39(4):339-44.
Pickering C, Grgic J. Caffeine and exercise: what next? Sports Med. 2019;49(7):1007-30.
Williams Textbook of Endocrinology. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, editors. Williams Textbook of Endocrinology. 14th ed. Philadelphia: Elsevier. 2020.
Gild ML, Stuart M, Clifton-Bligh RJ, Kinahan A, Handelsman DJ. Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge. J Clin Endocrinol Metab. 2022;107(9):e3562-73.
Sonksen PH. Hormones and Sport-Insulin, growth hormone and sport. J Endocrinol. 2001;170(1):13-26.
Salvatore D, Simonides WS, Dentice M, Zavacki AM, Larsen PR. Thyroid hormones and skeletal muscle--new insights and potential implications. Nat Rev Endocrinol. 2014;10(4):206-14.
Cadwallader AB, De La Torre X, Tieri A, Botrè F. The abuse of diuretics as performance‐enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis. Brit J Pharmacol. 2010;161(1):1-6.
Arumugham V, Shahin M. Therapeutic uses of diuretic agents. StatPearls. 2023.
Armstrong LE, Costill DL, Fink WJ. Influence of diuretic-induced dehydration on competitive running performance. Med Sci Sports Exerc. 1985;17(4):456-61.
Shankara-Narayana N, Yu C, Savkovic S, Desai R, Fennell C, Turner L, et al. Rate and extent of recovery from reproductive and cardiac dysfunction due to androgen abuse in men. J Clin Endocrinol Metabol. 2020;105(6):1827-39.
Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, et al. Prolonged hypogonadism in males following withdrawal from anabolic–androgenic steroids: an under‐recognized problem. Addiction. 2015;110(5):823-31.
Rasmussen JJ, Selmer C, Østergren PB, Pedersen KB, Schou M, Gustafsson F, et al. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study. PloS One. 2016;11(8):e0161208.
Smit DL, Buijs MM, De Hon O, Den Heijer M, De Ronde W. Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study. Human Reprod. 2021;36(4):880-90.
Pope Jr HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiat. 1988;145(4):487-90.
Sharma A, Grant B, Islam H, Kapoor A, Pradeep A, Jayasena CN. Common symptoms associated with usage and cessation of anabolic androgenic steroids in men. Best Practice Res Clin Endocrinol Metabol. 2022;36(5):101691.
Cohen J, Collins R, Darkes J, Gwartney D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. J Int Society Sports Nutrit. 2007;4(1):12.
Karavolos S, Reynolds M, Panagiotopoulou N, McEleny K, Scally M, Quinton R. Male central hypogonadism secondary to exogenous androgens: a review of the drugs and protocols highlighted by the online community of users for prevention and/or mitigation of adverse effects. Clin Endocrinol. 2015;82(5):624-32.
Bonnecaze AK, O’Connor T, Aloi JA. Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men. Am J Men’s Health. 2020;14(6):1557988320966536.
Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exercise. 2006;38(4):644-51.
de Ronde W, Smit DL. Anabolic androgenic steroid abuse in young males. Endocrine Connections. 2020;9(4):R102-11.
Van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regulatory Toxicol Pharmacol. 2010;57(1):117-23.
Brennan BP, Kanayama G, Hudson JI, Pope, Jr HG. Human growth hormone abuse in male weightlifters. Am J Addictions. 2011;20(1):9-13.
Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope Jr HG. Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications. Drug Alcohol Dependence. 2010;109(1-3):6-13.
World Health Organization. Global status report on physical activity and health. Geneva: WHO; 2024.
Star S. The quest for harmonisation in anti-doping: an Indian perspective. Int Sports Law J. 2023;23(1):44-63.
El Osta R, Almont T, Diligent C, Hubert N, Eschwège P, Hubert J. Anabolic steroids abuse and male infertility. Basic Clin Androl. 2016;26(1):2.
Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev. 2019;7(1):84-94.
Busardo F, Frati P, Di Sanzo M, Napoletano S, Pinchi E, Zaami S, Fineschi V. The impact of nandrolone decanoate on the central nervous system. Curr Neuropharmacol. 2015;13(1):122-31.
Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the U nited States. Jama. 1993;270(10):1217-21.
Piacentino D, D Kotzalidis G, Del Casale A, Rosaria Aromatario M, Pomara C, Girardi P, Sani G. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Current Neuropharmacol. 2015;13(1):101-21.
Handelsman DJ, Hirschberg AL, Bermon S. Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance. Endocr Rev. 2018;39(5):803-29.
Hildebrandt T, Harty S, Langenbucher JW. Fitness supplements as a gateway substance for anabolic-androgenic steroid use. Psychol Addict Behav. 2012;26(4):955-62.
Neri M, Bello S, Bonsignore A, Cantatore S, Riezzo I, Turillazzi E, Fineschi V. Anabolic androgenic steroids abuse and liver toxicity. Mini Rev Med Chem. 2011;11(5):430-7.
Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA network open. 2018;1(6):e183337.
Al-Saad N, Aljaal S, Alessa J, Santhosh ME. Systematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport. Front Sports Active Living. 2026;8:1740663.
Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004-10.
Jastreboff AM, Kaplan LM, Hartman ML. Triple-hormone-receptor agonist retatrutide for obesity. N Eng J Med. 2023;389(17):1629-30.
Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OH, Peters TM, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann Internal Med. 2025;178(2):199-217.
Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int Obesity. 2025;49(3):433-51.
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36.
Downloads
Published
How to Cite
Issue
Section
